Drug-induced liver injury (DILI) is a potential complication of nearly all classes of medication. It's not at all uncommon for DILI to pass undetected
CN Bio and iiCON announce COVID-19 research collaboration
Partnership focused on validation of novel Organ-on-a-Chip infection models Human-relevant single and multi-organ SARS-CoV-2 infected models
CN Bio expands service offering to support oncology drug discovery
New Oncology Service supports unique in vitro investigations into the PK/PD relationship Harnesses CN Bio’s proprietary PhysioMimix™ PK system
Changing Times, Why Pharmacokinetics Matter in Drug Discovery
Drug discovery should be simple. Deliver the right molecule, antibody, new modality, or cell to the right target within the right organ at the right
CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University
Enables accurate modelling of the human colon and the mucosal barrier Provides new insights to the relationship between human microbiome and effect
Lonza and CN Bio Announce Distribution Agreement
Lonza and CN Bio Announce Distribution Agreement Providing Prevalidated Hepatocytes for Use on Innovative Organ-on-a-chip Range Through a new
Of Mice and Men – Will human organ-on-a-chip disease models replace animal use?
The aim of organ-on-a-chip (OOC) technology is to more accurately replicate human physiology in vitro to overcome the relevance limitations of current
CN Bio’s PhysioMimix™ adopted by King’s College London to investigate chronic liver disease
Next generation organ-on-a-chip (OOC) technology to be used to investigate the human gut microbiome for improving outcomes for patients with liver
Cell4Pharma agreement
Today we signed a supply agreement with Dutch Company Cell4Pharma to access their industry-validated conditionally immortalised Renal Proximal Tubule